- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02209792
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patient of 18 to 65 years of age
- Provision of written informed consent in accordance with Good Clinical Practice and local legislation prior to any study procedures
- Diagnosis of Crohn's disease documented for at least 6 months. Preferably, inflammatory activity of the bowel should be confirmed by endoscopy within the last 3 months
- Moderate to severe Crohn's disease, CDAI ≥220 to ≤450, at baseline (visit 2)
Any of the following therapy, provided the respective criteria for dosage, duration and stability were satisfied:
- Prednisone or other systemic corticosteroids for at least 12 weeks with a stable oral dosage ≤25 mg/d or equivalent for at least two weeks prior to visit 2
- Budesonide with a stable dose of ≤ 9 mg/d for at least 2 weeks prior to visit 2 (changed by amendment 1, dated 16 January 2002)
- 5-Aminosalicylic Acid drugs/derivatives, provided they were given for 3 months or more and the dosage was stable for at least 4 weeks prior to visit 2
- 6-Mercaptopurine or azathioprine, provided they were taken for 6 months or more and the dosage was stable for at least 12 weeks prior to visit 2
- Methotrexate, provided it was taken for 6 months or more and the dosage was stable and ≤25 mg per week for at least 12 weeks prior to visit 2
The following patients were included in the 18-week treatment extension:
Patients who received BIRB 796 BS for 8 weeks and reached:
- Clinical remission (defined as CDAI <150) after 8 weeks or
- Clinical response (reduction of CDAI ≥70) after 8 weeks
- Patients who were willing to continue with their treatment
Exclusion Criteria:
- Pregnancy (to be excluded at visit 2 by urine β-human chorion-gonadotropin-test in women of childbearing potential) or breast feeding
- Female patients of childbearing potential (not 6 months post-menopausal or surgically sterilised) not using an approved form of birth control (hormonal contraceptives orally or in depot, intrauterine device)
- Patients without signs of inflammation of the bowel in the initial colonoscopy of the substudy
- Patients with colostomy or ileostomy
- Planned or needed surgery during the conduct of the trial due to Crohn's disease or for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage
- Known or suggested severe fixed symptomatic stenosis of the small or large intestine
- Severe underlying disease in particular of the GI tract (e.g. irritable bowel syndrome, celiac disease, infectious colitis)
- Patients with pathogens or Clostridium difficile toxin detected in the stool culture in the screening period
- Other infectious, ischemic, or immunological diseases with gastrointestinal involvement
- Patients with short bowel syndrome
- Patients who had had a treatment failure with a tumor necrosis factor (TNF)-blocking agent. Treatment failure was defined as not achieving a clinical response (improvement of ≥70 points in CDAI within 4 weeks) in a clinical trial or - in clinical practice -discontinuation of the TNF-blocking agent due to ineffectiveness (changed according to amendment 1, dated 16 January 2002)
- Treatment with cyclosporine A within 12 weeks prior to visit 2
Last dose given within the specified time period before visit 2 for the following compounds:
- infliximab (Remicade®): 8 weeks,
- investigational agent: 4 weeks or 5 half-lives, whichever is longer
- Treatment with anti-inflammatory medication deviating from the criteria for dosage, and stability as provided in the inclusion criteria
Patients treated with any of the following therapy:
- antibiotics provided the dosage had not been stable within 2 weeks prior to visit 2;
- parenteral or elemental diet;
- intrarectal therapy for Crohn's disease 2 weeks prior to visit 2 (added by amendment 1, dated 16 January 2002)
Treatment with:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to visit 2;
- Acetylsalicylic acid >100 mg/d;
- Paracetamol (acetaminophen) >3 g/day;
- Drug classified as proton pump inhibitor: 7 days prior to visit 2. This exclusion criterion was deleted after amendment 2 dated 11 June 2002.
- Drug classified as H2-receptor-blocker or antacid: 2 days prior to visit 2. This exclusion criterion was deleted after amendment 2 dated 11 June 2002.
- Active infection or serious infectious diseases resulting in hospitalisation or requiring systemic anti-infective therapy within 4 weeks before visit 2
- Serologic evidence of active hepatitis B and/or C
- Known HIV-infection
- History of prior tuberculosis infection or suspicion of active infection at screening based on chest X-ray done within 6 months prior to treatment phase
- History of cardiovascular, renal, neurologic, psychiatric, liver, immunologic, or endocrine dysfunction if they were clinically significant. A clinically significant disease was defined as one which, in the opinion of the investigator, may have either put the patient at risk because of participation in the study or as a disease which may have influenced the results of the study or the patient's ability to participate in the study
- Recent history of heart failure (one year or less) or myocardial infarction or patients with any cardiac arrhythmia requiring drug therapy (changed by amendment 1, dated 16 January 2002)
- ECG results outside of the reference range of clinical relevance including, but not limited to QTcB >480 msec, PR interval >240 msec, QRS interval >110 msec
- History of malignant disease in the last 5 years or suspicion of active malignant disease except successfully treated squamous or basal cell carcinoma of the skin and except patients with cervical carcinoma in situ who have had adequate treatment and follow up
- Clinically significant abnormal baseline haematology, blood chemistry or urinalysis if the abnormality defines a disease listed as an exclusion criterion
Any of the following specific laboratory abnormalities at visit 1:
- alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than upper limit of normal range (ULN)
- Total bilirubin greater than ULN except for patients with documented Gilbert's disease
- Gamma-glutamyltransferase, alkaline phosphatase or lactate dehydrogenase greater than 1.5 x ULN
- White blood cell count greater than 1.5 ULN which was not due to Crohn's disease as assessed by the investigator
- Serum creatinine above 1.5 x ULN
- History of drug or alcohol abuse within the past two years or active drug or alcohol abuse
- Participation in another clinical trial within 4 weeks or 5 half-lives of the respective investigational agent, whichever was longer
- Hypersensitivity to trial drug
- Inability to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIRB 796 BS, low dose
2 x 5 mg b.i.d.
|
|
Experimental: BIRB 796 BS, medium dose 1
20 mg b.i.d.
|
|
Experimental: BIRB 796 BS, medium dose 2
2 x 5 mg + 20 mg b.i.d.
|
|
Experimental: BIRB 796 BS, high dose
3 x 20 mg b.i.d.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Remission defined as Crohn's Disease Activity Index (CDAI) < 150
Time Frame: at week 8
|
at week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical remission (defined as a CDAI score below 150)
Time Frame: at week 26
|
at week 26
|
|
Stabilised clinical remission at the end of the main treatment phase
Time Frame: at week 8 and 10
|
at week 8 and 10
|
|
Time to clinical remission
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Duration of maintenance of clinical remission
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Clinical response (defined as a reduction of CDAI score ≥70)
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Time to clinical response
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Duration of maintenance of clinical response
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the CDAI score
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Number of patients with 50% fistulae reduction
Time Frame: up to 26 weeks
|
defined as an at least 50% reduction from baseline in the number of draining fistulae
|
up to 26 weeks
|
Changes from baseline in the number of draining fistulae
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in C-reactive protein (CRP) measurements
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Changes from baseline in the daily corticosteroid dose
Time Frame: after week 10
|
measured in mg prednisone equivalent
|
after week 10
|
Number of drop-outs due to treatment failure
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Number of patients with adverse events
Time Frame: up to 40 weeks
|
up to 40 weeks
|
|
Number of patients with clinically relevant changes in laboratory parameters
Time Frame: up to week 38
|
up to week 38
|
|
Number of patients with relevant findings in electrocardiogram (ECG)
Time Frame: up to 26 weeks
|
up to 26 weeks
|
|
Extended clinical response (defined as a reduction of CDAI score ≥ 100)
Time Frame: week 10 to 26
|
week 10 to 26
|
|
Time to extended clinical response
Time Frame: week 10 to 26
|
week 10 to 26
|
|
Duration of maintenance of extended clinical response
Time Frame: week 10 to 26
|
week 10 to 26
|
|
Changes from baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) score
Time Frame: at the end of week 8
|
for patients in the endoscopic substudy only
|
at the end of week 8
|
Changes from baseline in the histological scoring of biopsy specimens
Time Frame: at the end of week 8
|
for patients in the endoscopic substudy only
|
at the end of week 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1175.12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States